New drug-eluting stent platforms to prevent stent thrombosis.
Although earlier reports from randomized controlled clinical trials suggested that the incidence of stent thrombosis following drug-eluting stent (DES) implantation was similar to or less than that observed following bare-metal stent deployment, longer-term follow-up has revealed a persistent, protracted risk for thrombosis following DES. This apparent divergence in risk for thrombosis becomes evident beyond 6 to 12 months following deployment. The proposed etiologies of late DES thrombosis are multifactorial and differ somewhat from those factors incriminated in bare-metal stent thrombosis. Prevention strategies are in development to address polymer hypersensitivity/inflammatory response, delayed endothelialization/vessel healing, late incomplete stent apposition, persistence of the underlying endoluminal metal prosthesis, and discontinuation of antiplatelet therapies.
Kereiakes
Dean J
DJ
Heart Center of Greater Cincinnati and Lindner Center at Christ Hospital, Cincinnati, Ohio, USA.
D019917:Blood Vessel Prosthesis Implantation / Q000295:instrumentation*; D020099:Coated Materials, Biocompatible; D003328:Coronary Thrombosis / Q000517:prevention & control*; D004341:Drug Evaluation; D006083:Graft Occlusion, Vascular / Q000517:prevention & control*; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D011474:Prosthesis Design; D011475:Prosthesis Failure; D015607:Stents
D020099:Coated Materials, Biocompatible; D010975:Platelet Aggregation Inhibitors